×
Abstract GS6-04: The EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS6-04

Mar 15th, 2018 - Background: In the neoadjuvant treatment setting of ER+/HER2- breast cancer (BC) the choice between preoperative endocrine - (NET) or preoperative chemotherapy (NCT) is largely based on the expression of hormone receptors (HR), grading and possibly Ki-67. The EndoPredict 12-gene molecular score (EP) is a validated prognostic score based on the expression of genes involved in cellular processes ...

Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-14-03

Sep 28th, 2018 - Background: Talazoparib (TALA) is a dual-mechanism poly (ADP-ribose) polymerase (PARP) inhibitor that traps PARP on DNA. Efficacy results of this phase 2 trial were previously presented (Turner et al, ASCO 2017, abstract 1007). This study included sparse pharmacokinetic (PK) sampling for patients through cycle 4 of therapy. Exploratory analyses included assessment of exposure versus parameters ...

Abstract GS4-04: Randomized blinded sham- and waitlist-controlled trial of acupuncture for joint symptoms related to aromatase inhibitors in women with early stage breast cancer (S1200)
http://cancerres.aacrjournals.org/content/78/4_Supplement/GS4-04

Mar 19th, 2018 - Background: Musculoskeletal symptoms are the most common side effect of aromatase inhibitors (AIs) and can result in decreased quality of life and discontinuation of therapy. Pilot data from two prior single institution studies showed that acupuncture decreased AI-induced joint symptoms in breast cancer (BC) patients. Methods: We conducted a SWOG multicenter randomized controlled trial among po...

Abstract P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-14-05

Sep 29th, 2018 - Background: Ribociclib (Kisqali®) is a CDK4/6 inhibitor, recently approved in the U.S. as a first line therapy for HR+/HER2- advanced breast cancer (ABC) in combination with an aromatase inhibitor. The recommended starting dose is 600 mg/day orally (3 wks-on/1 wk-off). Ribociclib inhibits CYP3A4 and its metabolism is mostly CYP3A4-mediated. Here we evaluate the effect of food, conmeds and speci...

Abstract CS1-2: Searching for the optimal duration of adjuvant endocrine therapy in breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/CS1-2

Mar 28th, 2018 - Endocrine therapy is an integral part of the adjuvant systemic management of women with early stage hormone receptor-positive breast cancer. Adjuvant endocrine therpay is associated with significant improvements in disease-free and overall survival. Several adjuvant endocrine therapy approaches are available to women based on their menopausal status, disease stage, tumor characteristics, co-mor...

Abstract P3-14-01: Effects of adding budesonide or colestipol to loperamide prophylaxis on neratinib-associated diarrhea in patients with HER2+ early-stage breast cancer: The CONTROL trial
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-14-01

Jan 2nd, 2019 - Background: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor. Results from the randomized, placebo-controlled, Phase III ExteNET study demonstrated that neratinib significantly improves 24-month iDFS in patients (pts) with trastuzumab-treated early-stage HER2+ breast cancer (HR 0.67; 95% CI 0.50–0.91; p=0.009) [Chan et al. Lancet Oncol 2016]. In ExteNET, loperamide prophylaxis was...

Abstract P1-14-04: Overall survival in metastatic breast cancer patients in the third millennium: Results of an Italian study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-14-04

Oct 2nd, 2018 - BACKGROUND - Metastatic breast cancer (MBC) is a life-threatening disease. It is important to provide data about real-life MBC patients (pts) to understand the current prognostic factors. The aim of the present observational study, named COSMO (Checking Overall Survival in a MBC Observational study) is to describe the overall survival (OS) in a large cohort of MBC pts, assessing its correlation...

Abstract P3-14-10: Proposed biosimilar pegfilgrastim LA-EP2006 shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-14-10

Jan 4th, 2019 - Background: Granulocyte colony-stimulating factors such as filgrastim and its long-acting version pegfilgrastim are widely used to prevent neutropenia in patients receiving chemotherapy. LA-EP2006 is a proposed biosimilar pegfilgrastim that has been compared with reference pegfilgrastim and shown to have no clinically meaningful differences regarding efficacy and safety in breast cancer patient...

Abstract ES2-3: Managing increased breast cancer risk based on high and moderate penetrance gene mutations
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES2-3

Apr 8th, 2018 - Genetic testing in the modern era increasingly examines multiple genes using next generation technologies. Most assays include the high penetrance genes, which confer lifetime breast cancer risk greater than 5-fold, include BRCA1/2, TP53, CDH1 and PALB2. Moderate penetrance genes are associated with lifetime breast cancer risk in the range of 2-3 fold, and include ATM, NF1, CHEK2 (mutation-spec...

Abstract ES7-1: Challenges in the management of locoregional recurrence
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES7-1

Apr 17th, 2018 - The increasing trend toward tailoring treatment of the primary breast cancer with limited surgery of both the breast and axilla has increased the challenge of managing locoregional recurrence (LRR). In the era when patients uniformly had axillary dissection, the appropriateness of repeat sentinel node biopsy was not a question. Similarly, the dogma that all ipsilateral breast tumor recurrences ...

Abstract ES8-2: Exosome analysis in breast cancer: Clinical translation
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES8-2

Apr 12th, 2018 - There is a growing appreciation that tumor secreted factors can function by orchestrating the cross-talk between cancer, stromal and immune cells. Tumors constitutively release membrane-derived extracellular vesicles (EVs) or exosomes that are readily detected in body fluids and have been appreciated to play important roles in signaling, immunomodulation and metastasis. We examined the role of ...

Abstract ES4-3: Can we improve treatment tailoring in advanced HER2+ breast cancer?
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES4-3

Apr 21st, 2018 - In the 1980s the importance of HER2 signalling to the aberrant behaviour of certain breast cancer cells was recognized for the first time. The intervening 3 decades have seen an immense international translational and clinical research effort that at first identified a hitherto unknown subtype of breast cancer – HER2-positive breast cancer - and then went on to entirely transform the natural hi...

Abstract ES10-1: Genetic dissection of cancer development, therapy response, and resistance in mouse models of breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES10-1

Apr 16th, 2018 - Genetically engineered mouse models (GEMMs) and patient-derived xenograft (PDX) models of breast cancer have proven invaluable for basic and translational cancer research. These preclinical models have been useful for in vivo analysis of breast cancer initiation and progression, as well as for investigating anti-tumor efficacy of targeted drugs and immunotherapeutics. However, the establishment...

Abstract ES4-2: Adjuvant therapy for HER2-positive breast cancers: is less more?
http://cancerres.aacrjournals.org/content/78/4_Supplement/ES4-2

Apr 20th, 2018 - The use of trastuzumab-based chemotherapy has dramatically improved outcome for patients with early stage HER2-positive breast cancer. Given the excellent outcomes seen to date and the toxicities associated with therapy, it is critical to establish whether additional therapies can further improve outcome, and conversely if there are patients who would have a favorable outcome with less therapy....

Abstract P1-17-01: Development of brain metastases in breast cancer patients treated in the neoadjuvant trials Geparquinto and Geparsixto
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-01

Oct 6th, 2018 - Background: The incidence of brain metastases (BM) in breast cancer patients is rising and has become a major clinical challenge. So far, the incidence of BM after modern neoadjuvant treatment is not clear. Materials and Methods: In Geparquinto, patients with untreated HER2-positive breast cancer (n=615) received either lapatinib or trastuzumab, patients with HER2 negative breast cancer (n=1925...

Abstract MS2-2: Understanding the unique biology of ILC
http://cancerres.aacrjournals.org/content/78/4_Supplement/MS2-2

Apr 29th, 2018 - Invasive lobular breast cancer (ILC) is characterized by distinct etiological, pathological, and clinical features, yet the underlying biology is poorly understood. To extend the molecular determinants of ILC beyond the well-known loss of E-cadherin, we combined a plethora of in silico and wet-bench approaches, and comprehensively characterized ILC tumor models and clinical samples. In support ...

Abstract MS2-3: Tailoring systemic therapy for patients with lobular breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/MS2-3

Apr 28th, 2018 - Recent developments in breast cancer treatment include an increasing awareness of the role of systemic therapies in selected subgroups of patients. A consequence of this strategy is the importance of accurate and reliable histopathological assessment. Through the identification of lobular breast cancer, that account for up to 15% of all invasive breast carcinomas, it is possible to select patie...

Abstract P1-17-10: Survival outcomes related to health care coverage in breast cancer patients with brain metastases in Brazil: A sub-analysis from the LACOG-0312 study
http://cancerres.aacrjournals.org/content/78/4_Supplement/P1-17-10

Oct 8th, 2018 - Background The incidence of brain metastases among women with metastatic breast cancer (MBC) ranges from 10 to 30% depending of breast cancer (BC) subtype. Inequities in the access to optimal treatment and shorter survival of BC by type of health care coverage were previously reported in an observational study in Brazil. The present analysis aims to analyze the impact of the type of health care...

Abstract P3-14-07: Early detection of chemotherapy-induced cardiotoxicity in breast cancer patients
http://cancerres.aacrjournals.org/content/78/4_Supplement/P3-14-07

Jan 8th, 2019 - BACKGROUND The incidence of cardiotoxicity in patients receiving treatment for breast cancer is unknown. There is not enough evidence about early detection and appropriate management of cardiotoxicity. The aim of this study is to identify early markers of risk of cardiac toxicity. MATERIAL AND METHOD Prospective study was conducted between 2014 and 2017 based on a cohort of 97 patients diagnose...

Abstract P5-09-02: Tβ4 expression in cancer-associated endothelial cells enhances progression of invasive breast cancer
http://cancerres.aacrjournals.org/content/78/4_Supplement/P5-09-02

Jan 9th, 2019 - Background: Invasive breast cancer is a highly aggressive primary breast tumour with poor prognosis. As tumour angiogenesis is exhibited by invasive breast cancer, anti-angiogenic therapy has been intensively evaluated over the past decade. However, clinical studies were disappointing. Thymosin β4 (Tβ4), a multi-functional peptide, is associated with induction of angiogenesis, but the role of T...